BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 21342321)

  • 41. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
    Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
    Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
    Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
    Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism.
    Dressler R; Laut J; Lynn RI; Ginsberg N
    Clin Nephrol; 1995 May; 43(5):324-31. PubMed ID: 7634548
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
    Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
    Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
    Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
    Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
    Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.
    Ohashi N; Uematsu T; Nagashima S; Kanamaru M; Togawa A; Hishida A; Uchida E; Akizawa T; Koshikawa S
    Br J Clin Pharmacol; 2004 Jun; 57(6):726-34. PubMed ID: 15151518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
    Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
    Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
    Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
    Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.
    Marco MP; Martínez I; Amoedo ML; Borràs M; Saracho R; Almirall J; Fibla J; Fernández E
    Kidney Int; 1999 Oct; 56(4):1349-53. PubMed ID: 10504487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
    Zwiech R; Dryja P; Łacina D; Nykiel P; Sek-Szczepanowska K; Bratkowska K; Pietrzak B; Chrul S
    Wiad Lek; 2011; 64(4):267-73. PubMed ID: 22533150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
    Tamura S; Ueki K; Mashimo K; Tsukada Y; Naitoh M; Abe Y; Kawai H; Tsuchida A; Wakamatsu R; Nojima Y
    Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cinacalcet effect on severe hyperparathyroidism.
    Al Saran K; Sabry A; Yehia A; Molhem A
    Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):867-71. PubMed ID: 20814122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients.
    Bechtel U; Mücke C; Feucht HE; Schiffl H; Sitter T; Held E
    Am J Kidney Dis; 1995 Feb; 25(2):291-6. PubMed ID: 7847357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival - a single-centre study in a stage 5 chronic kidney disease population.
    Fotheringham J; Balasubramanian SP; Harrison B; Wilkie M
    Nephron Clin Pract; 2011; 119(2):c113-20. PubMed ID: 21757948
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
    Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
    Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.